Are you Dr. Garraway?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 92 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# D1542
Boston, MA 02115Phone+1 617-632-6689
Summary
- Dr. Levi Garraway, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and is an Associate Professor at Harvard Medical School.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2001
Harvard Medical SchoolClass of 1999
Certifications & Licensure
MA State Medical License 2001 - 2018
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- Whole-Exome Sequencing (WES) of Cancer Patients Start of enrollment: 2012 Sep 01
Publications & Presentations
PubMed
- 443 citationsFusobacterium nucleatum and T Cells in Colorectal Carcinoma.Kosuke Mima, Yasutaka Sukawa, Reiko Nishihara, Zhi Rong Qian, Mai Yamauchi
JAMA Oncology. 2015-08-01 - 1095 citationsDivergent clonal evolution of castration-resistant neuroendocrine prostate cancerHimisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca
Nature Medicine. 2016-03-01 - 190 citationsClinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.David Liu, Elizabeth R. Plimack, Jean H. Hoffman-Censits, Levi A. Garraway, Joaquim Bellmunt
JAMA Oncology. 2016-08-01
Press Mentions
Roche’s Itovebi Regimen Shows Significant Survival Benefits for HR-Positive Breast Cancer in Phase III Trial ResultsOctober 31st, 2024- New England Journal of Medicine Publishes Landmark Phase III Results for Roche’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast CancerOctober 31st, 2024
- New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast CancerOctober 30th, 2024
- Join now to see all
Grant Support
- The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
- High-Throughput Tumor Genomic Profiling By Massively Parallel SequencingNational Cancer Institute2011
- High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2010–2011
- Integrated Functional Genomic Analyses Of MelanomaNational Cancer Institute2005–2009
- Functional Analysis Of The PTEN Tumor Suppressor ProteinNational Cancer Institute2005–2009
- High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2007–2008
- Defining Melanoma Therapeutic Avenues By Integrative Functional GenomicsOffice Of The Director, National Institutes Of Health2007
- Molecular Genetics Of Parasite VirulenceNational Human Genome Research Institute1992–1998
Professional Memberships
- Member
